Insights & Resources

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Although the SEC withdrew its climate disclosure rule, state and international regulations still require businesses to manage emissions and climate risks.

Establishing effective ESG KPIs is critical in today’s complex environment. We outline key considerations to drive sustainable success.

Weaver conducted a climate risk analysis to assess and mitigate natural disaster impacts, ensuring resilience and sustainability in our U.S. locations.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Weaver has developed carbon accounting processes to determine our carbon footprint across Scope 1 and Scope 2 emissions.

Microsoft has reformed the calculation of its supply-chain emissions through innovative accounting to align with its carbon-negative 2030 goals. Learn more here.

CEOs can leverage established ESG principles and best practices to create sustainable business operations and promote long-term growth.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

The energy sector has been marked by its market volatility lately. CEOs in the industry can use established ESG principles to create sustainable business practices.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.